{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:54Z","timestamp":1792783494793,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The University of Queensland","id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40262-026-01659-9","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:31:33Z","timestamp":1787992293000},"page":"1553-1564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1232-5761","authenticated-orcid":false,"given":"Matthieu","family":"Gregoire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayoung","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Patricia","family":"Hern\u00e1ndez-Mitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd H.","family":"Abdul-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"6","key":"1659_CR1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JWC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper#. Intensive Care Med. 2020;46(6):1127\u201353. https:\/\/doi.org\/10.1007\/s00134-020-06050-1.","journal-title":"Intensive Care Med"},{"issue":"1","key":"1659_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR). Crit Care. 2019;23(1):104. https:\/\/doi.org\/10.1186\/s13054-019-2378-9.","journal-title":"Crit Care"},{"issue":"1","key":"1659_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/FTD.0000000000000940","volume":"44","author":"MH Abdul-Aziz","year":"2022","unstructured":"Abdul-Aziz MH, Brady K, Cotta MO, Roberts JA. Therapeutic drug monitoring of antibiotics: defining the therapeutic range. Ther Drug Monit. 2022;44(1):19\u201331. https:\/\/doi.org\/10.1097\/FTD.0000000000000940.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"1659_CR4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072\u201383. https:\/\/doi.org\/10.1093\/cid\/ciu027.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1659_CR5","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1128\/AAC.00951-13","volume":"57","author":"G Wong","year":"2013","unstructured":"Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, et al. Protein binding of \u03b2-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57(12):6165\u201370. https:\/\/doi.org\/10.1128\/AAC.00951-13.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1659_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030515","volume":"12","author":"P Gandia","year":"2023","unstructured":"Gandia P, Decheiver S, Picard M, Guilhaumou R, Baklouti S, Concordet D. Hypoalbuminemia and pharmacokinetics: when the misunderstanding of a fundamental concept leads to repeated errors over decades. Antibiotics. 2023;12(3):515. https:\/\/doi.org\/10.3390\/antibiotics12030515.","journal-title":"Antibiotics"},{"issue":"10","key":"1659_CR7","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1002\/jps.21317","volume":"97","author":"NJ Waters","year":"2008","unstructured":"Waters NJ, Jones R, Williams G, Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci. 2008;97(10):4586\u201395. https:\/\/doi.org\/10.1002\/jps.21317.","journal-title":"J Pharm Sci"},{"issue":"5","key":"1659_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4155\/bio.13.338","volume":"6","author":"B Buscher","year":"2014","unstructured":"Buscher B, Laakso S, Mascher H, Pusecker K, Doig M, Dillen L, et al. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of The European Bioanalysis Forum. Bioanalysis. 2014;6(5):673\u201382. https:\/\/doi.org\/10.4155\/bio.13.338.","journal-title":"Bioanalysis"},{"issue":"1","key":"1659_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/FTD.0000000000000675","volume":"42","author":"MH Al-Shaer","year":"2020","unstructured":"Al-Shaer MH, Alghamdi WA, Graham E, Peloquin CA. Meropenem, cefepime, and piperacillin protein binding in patient samples. Ther Drug Monit. 2020;42(1):129\u201332. https:\/\/doi.org\/10.1097\/FTD.0000000000000675.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1659_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/FTD.0000000000000602","volume":"41","author":"S Colman","year":"2019","unstructured":"Colman S, Stove V, De Waele JJ, Verstraete AG. Measuring unbound versus total piperacillin concentrations in plasma of critically ill patients: methodological issues and relevance. Ther Drug Monit. 2019;41(3):325\u201330. https:\/\/doi.org\/10.1097\/FTD.0000000000000602.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1659_CR11","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jpba.2005.05.027","volume":"39","author":"A Isla","year":"2005","unstructured":"Isla A, Arzuaga A, Maynar J, Gasc\u00f3n AR, Solin\u00eds MA, Corral E, et al. Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC. J Pharm Biomed Anal. 2005;39(5):996\u20131005. https:\/\/doi.org\/10.1016\/j.jpba.2005.05.027.","journal-title":"J Pharm Biomed Anal"},{"key":"1659_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jpba.2017.10.023","volume":"148","author":"S Naicker","year":"2018","unstructured":"Naicker S, Guerra Valero YC, Ordenez Meija JL, Lipman J, Roberts JA, Wallis SC, et al. A UHPLC-MS\/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. J Pharm Biomed Anal. 2018;148:324\u201333. https:\/\/doi.org\/10.1016\/j.jpba.2017.10.023.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"1659_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/FTD.0000000000000827","volume":"43","author":"S Schie\u00dfer","year":"2021","unstructured":"Schie\u00dfer S, Hitzenbichler F, Kees MG, Kratzer A, Lubnow M, Salzberger B, et al. Measurement of free plasma concentrations of beta-lactam antibiotics: an applicability study in intensive care unit patients. Ther Drug Monit. 2021;43(2):264\u201370. https:\/\/doi.org\/10.1097\/FTD.0000000000000827.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"1659_CR14","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1093\/jac\/dkab314","volume":"76","author":"E Wallenburg","year":"2021","unstructured":"Wallenburg E, Ter Heine R, de Lange DW, van Leeuwen H, Schouten JA, Ten Oever J, et al. High unbound flucloxacillin fraction in critically ill patients. J Antimicrob Chemother. 2021;76(12):3220\u20138. https:\/\/doi.org\/10.1093\/jac\/dkab314.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1659_CR15","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/bcp.13673","volume":"84","author":"PKL Chin","year":"2018","unstructured":"Chin PKL, Drennan PG, Gardiner SJ, Zhang M, Dalton SC, Chambers ST, et al. Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with Staphylococcus aureus bacteraemia. Br J Clin Pharmacol. 2018;84(10):2311\u20136. https:\/\/doi.org\/10.1111\/bcp.13673.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1659_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/jac\/dkad368","volume":"79","author":"B Wulkersdorfer","year":"2024","unstructured":"Wulkersdorfer B, Bergmann F, Amann L, Fochtmann-Frana A, Al Jalali V, Kurdina E, et al. Effect of albumin substitution on pharmacokinetics of piperacillin\/tazobactam in patients with severe burn injury admitted to the ICU. J Antimicrob Chemother. 2024;79(2):262\u201370. https:\/\/doi.org\/10.1093\/jac\/dkad368.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1659_CR17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/FTD.0000000000000809","volume":"42","author":"U Liebchen","year":"2020","unstructured":"Liebchen U, Dorn C, Kees M, Schiesser S, Hitzenbichler F, Kees F, et al. Comment on \u201cmeropenem, cefepime, and piperacillin protein binding in patient samples.\u201d Ther Drug Monit. 2020;42(6):909. https:\/\/doi.org\/10.1097\/FTD.0000000000000809.","journal-title":"Ther Drug Monit"},{"key":"1659_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2020.122127","volume":"1146","author":"TNe Castro","year":"2020","unstructured":"Castro TNe, Costa ER, Gon\u00e7alves JCS, Estrela RdeCE. Pretreatment and non-specific binding in ultrafiltration device: impact on protease inhibitor quantification. J Chromatogr B. 2020;1146:122127. https:\/\/doi.org\/10.1016\/j.jchromb.2020.122127.","journal-title":"J Chromatogr B"},{"issue":"14","key":"1659_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/17576180.2024.2365526","volume":"16","author":"C Lier","year":"2024","unstructured":"Lier C, Dejaco A, Kratzer A, Kees MG, Kees F, Dorn C. Free serum concentrations of antibiotics determined by ultrafiltration: extensive evaluation of experimental variables. Bioanalysis. 2024;16(14):747\u201356.","journal-title":"Bioanalysis"},{"issue":"6","key":"1659_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4820","volume":"34","author":"C Dorn","year":"2020","unstructured":"Dorn C, Schie\u00dfer S, Wulkersdorfer B, Hitzenbichler F, Kees MG, Zeitlinger M. Determination of free clindamycin, flucloxacillin or tedizolid in plasma: pay attention to physiological conditions when using ultrafiltration. Biomed Chromatogr. 2020;34(6):e4820. https:\/\/doi.org\/10.1002\/bmc.4820.","journal-title":"Biomed Chromatogr"},{"key":"1659_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpba.2012.11.018","volume":"75","author":"C Wang","year":"2013","unstructured":"Wang C, Williams NS. A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds. J Pharm Biomed Anal. 2013;75:112\u20137. https:\/\/doi.org\/10.1016\/j.jpba.2012.11.018.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"1659_CR22","doi-asserted-by":"publisher","first-page":"446.e1","DOI":"10.1016\/j.cmi.2021.06.039","volume":"28","author":"E Wallenburg","year":"2022","unstructured":"Wallenburg E, Br\u00fcggemann RJM, Roberts JA, Jager NGL, Ulldemolins M, Wilkes S, et al. A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients. Clin Microbiol Infect. 2022;28(3):446.e1-446.e7. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.039.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"1659_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/jac\/dkae092","volume":"79","author":"NGL Jager","year":"2024","unstructured":"Jager NGL, Van Ewijk-Beneken Kolmer E, Aarnoutse R, Te Brake LHM. Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example. J Antimicrob Chemother. 2024;79(5):1187\u201390. https:\/\/doi.org\/10.1093\/jac\/dkae092.","journal-title":"J Antimicrob Chemother"},{"key":"1659_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jchromb.2014.06.034","volume":"965","author":"SM Illamola","year":"2014","unstructured":"Illamola SM, Labat L, Benaboud S, Tubiana R, Warszawski J, Tr\u00e9luyer JM, et al. Determination of total and unbound concentrations of lopinavir in plasma using liquid chromatography\u2013tandem mass spectrometry and ultrafiltration methods. J Chromatogr B. 2014;965:216\u201323. https:\/\/doi.org\/10.1016\/j.jchromb.2014.06.034.","journal-title":"J Chromatogr B"},{"issue":"1","key":"1659_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"1659_CR26","unstructured":"US Food and Drug Administration [FDA], \u201cGuidance for Industry: Bioanalytical Method Validation\u201d, May 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01659-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01659-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:20:06Z","timestamp":1790684406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01659-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01659-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article\n                      .","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SCW and JAR designed the study. SCW and HW carried out the analytical work. MG and SCW performed the data analysis. MG, SCW, PGW, HW, MPHM, MHAA and JAR contributed to the interpretation of results, drafting of the manuscript and critical revision.","order":2,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For patient inclusion in this study, ethical approval was obtained from The Prince Charles Hospital Human Research Ethics Committee (HREC\/18\/QPCH\/184) and The Royal Brisbane and Women\u2019s Hospital Human Research Ethics Committee (HREC\/2019\/QRBW\/55528).","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to participate was provided.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and analysed during the current study are not publicly available and their access remains at the discretion of the study investigators.","order":7,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}